Skip to main content

Table 3 Hypothesized effect after 1 year of treatment on the primary endpoint

From: The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients

Treatment arm

N

NFκB % change

1-β (power)

Arm A (placebo)

40

+ 5%

Arm B (metformin)

40

−13.5%

90%

Arm C (aspirin)

40

-13.5%

90%

Arm D (aspirin+metformin)

40

−55% (~ 3.0-fold the main effects)

80%